Q-omics provides the consensus-scored SPATA24 profile across patient tissues and cancer cell-line models. SPATA24 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SPATA24 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, SPATA24 RNA expression shows 18,681 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KICH, and ACC as cancer lineages where SPATA24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPATA24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPATA24 survival associations across molecular data types. SPATA24 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPATA24 RNA expression–survival associations across cancer types. High SPATA24 expression shows unfavorable associations in UVM, KICH, LIHC and COAD, but favorable associations in READ and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SPATA24 RNA expression.
This table summarizes SPATA24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for SPATA24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPATA24 shows lower tumor expression in KICH, COAD, KIRP and THCA and higher tumor expression in LIHC and HNSC. The KICH box plot shows higher SPATA24 RNA expression in normal versus tumor tissue (log2 FC = −2.001, t-test p < 0.001).
This table shows molecular features associated with SPATA24 in patient tissues and cancer cell lines. In patient samples, SPATA24 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SPATA24 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
